Chai Discovery raises $400M at $3.8bn as AI drug discovery moves from promise to deployment

Chai Discovery secured $400 million in Series C funding, boosting its valuation to $3.8 billion in just seven months. The San Francisco startup uses generative AI to design new antibodies and proteins, with its technology already adopted by major pharmaceutical companies like Eli Lilly and Pfizer.